Company Announcements QIAGEN’s first-quarter sales rose 13% at constant exchange rates, including 7% growth from acquisitions and a 1% decline from currency. At constant exchange rates, sales in the Americas, Europe/Middle East/Africa and Asia-Pacific grew 15%, 12% and 14% to make up 47%, 34% and 18% of sales, respectively. Seven emerging countries accounted for 10% […]
Canada’s 2013 budget for the Natural Sciences and Engineering Research Council (NSERC), announced in April, remained level at about CAD 1 billion ($970 million).The Canada Foundation for Innovation, which matches costs for high-end lab equipment, was designated CAD 500 million for five years. Funding will continue for prominent centers like TRIUMF, Canadian Light Source and […]
Funding for German universities and research institutes grew 23.0% to €15.5 billion ($20.4 billion) from 1998 to 2010, according to the Deutsche Forschungsgemeinschaft’s (DFG) May Funding Atlas 2012. Government and funding organization support grew 112.0% to €5.3 billion during the period to comprise 26% of total funding. The DFG, the Federal Ministry of Education and […]
According to Ernst & Young’s June report, 2011 revenues for public biotech firms in the US, Europe, Canada and Australia grew 10% on a normalized basis to $83.4 billion and R&D expenses rose 9% to $23.1 billion. US sales rose 12% to $58.8 billion on a normalized basis, with R&D spending up 9% to $17.2 […]
The European Commission (EC) will invest 16% of the €55 billion ($76.3 billion) research and innovation budget for its Seventh Framework Program (FP7) on the final call for research proposals. Allocations include €4.8 billion for “thematic research,” including €155 million for the Oceans of the Future Program, €147 million to fight antimicrobial resistance, €98 million […]
In its June World Preview 2018, EvaluatePharma forecasts the compound annual growth rate (CAGR) of global R&D spending by drug firms to reach $149 billion. R&D spending 2004–2010 grew at a CAGR of 6.5% to $128 billion. Year over year, the rate of R&D spending is expected to drop 0.3% in 2012 to $134 billion […]
In 2011, capital spending by chemical firms in the US, Europe and Japan covered by Chemical & Engineering News’s 2011 review grew 21.1%, 23.6% and 11.3% to $10.2 billion, $18.4 billion and $9.4 billion, respectively. The chemical firms with the highest capital spending were the US’s Dow Chemical, France’s Air Liquide and Germany’s Bayer, for […]
First-quarter revenues for the IBO Lab Equipment/Consumables Index grew 3.0%, 2.5% organically, to $4,088 million. Sales growth was hampered by lower capital spending in the US and Europe, including weak government and academic markets. Adjusted operating profit improved 5.0% to $743 million. Operating margin for the Index added 100 basis points to 19.2% of sales, […]
Millville, NJ 7/9/12—Wheaton has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing for an undisclosed amount. In addition, the companies have entered into a long-term strategic partnership for product development. CELLine Flasks are used in small-scale antibody and protein production for reduced culture and processing time.
Hillsboro, OR 7/9/12—FEI has purchased certain assets of AP Tech, its South Korean agent, for $12 million. Based in Suwon, South Korea, AP Tech has more than 40 employees. “This transition from an agent sales and service model to a direct presence in Korea is a natural evolution that fits both FEI’s strategic objectives as […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
